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ABSTRACT
Purpose Bariatric surgery is nowadays commonly applied as
treatment for morbid obesity (BMI>40 kg/m2). As informa-
tion about the effects of this procedure on a drug’s pharma-
cokinetics is limited, we aimed to evaluate the pharmacokinet-
ics of CYP3A probe substrate midazolam after oral and intra-
venous administration in a cohort of morbidly obese patients
that was studied before and 1 year post bariatric surgery.
Methods Twenty morbidly obese patients (aged 26–58 years)
undergoing bariatric surgery participated in the study of
which 18 patients returned 1 year after surgery. At both oc-
casions, patients received 7.5 mg oral and 5 mg intravenous
midazolam separated by 160±48 min. Per patient and occa-
sion, a mean of 22 blood samples were collected. Midazolam
concentrations were analyzed using population pharmacoki-
netic modeling.
Results One year after bariatric surgery, systemic clearance
of midazolam was higher [0.65 (7%) versus 0.39 (11%) L/min,
mean±RSE (P<0.01), respectively] and mean oral transit
time (MTT) was faster [23 (20%) versus 51 (15%) minutes
(P<0.01)], while oral bioavailability was unchanged (0.54
(9%)). Central and peripheral volumes of distribution were
overall lower (P<0.05).
Conclusions In this cohort study in morbidly obese patients,
systemic clearance was 1.7 times higher 1 year after bariatric
surgery, which may potentially result from an increase in he-
patic CYP3A activity per unit of liver weight. Although MTT
was found to be faster, oral bioavailability remained un-
changed, which considering the increased systemic clearance
implies an increase in the fraction escaping intestinal first pass
metabolism.
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ABBREVIATIONS
MTT Mean oral transit time
NPDE Normalized prediction distribution errors
OFV Objective function value
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INTRODUCTION
The prevalence of morbid obesity (body mass index, BMI
>40 kg/m2) is increasing worldwide. In the United States,
6% of the population is morbidly obese while in Europe prev-
alence of obesity (BMI >30 kg/m2) ranges between 10 and
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30% depending on the country (1,2). Exact numbers on the
prevalence of morbid obesity in Europe are lacking, but are
estimated to range between 1 and 7% (3–5).
Bariatric surgery is considered the most effective treatment
for morbid obesity (6,7). In 2011, more than 340,000 bariatric
surgeries, including Roux and – Y gastric bypass (RYGB) and
sleeve gastrectomy, were performed worldwide (8). During a
bariatric procedure, the stomach is reduced to a sleeve like
structure or a small pouch and, in case of a roux and –Y
gastric bypass, the duodenum and initial part of the small
intestine are bypassed (9–11). These alterations in the gastro-
intestinal tract may cause an increase in stomach pH, an in-
crease in gastric emptying time, and a decrease in the surface
area of absorption (9,12,13).
As such, a bariatric procedure may impact a drug’s phar-
macokinetics and have consequences for dosing. In particular
for drugs undergoing CYP3Ametabolism, it seems relevant to
study the impact of bariatric surgery, as the CYP3A enzyme
resides not only in the liver but also in the gut wall and is an
important drug metabolising enzyme involved in the metab-
olism of approximately 25% of all clinically used drugs (14).
Besides bariatric surgery induced anatomical changes to the
gastro-intestinal tract, the resulting reduction in (over)weight
may also influence CYP3A activity itself (15). It is well known
that obese patients suffer from low-grade inflammation caused
by macrophages and adipocytes in the adipose tissue which
excrete inflammation markers and adipokines, including Il-6
and TNF-alpha (16–18) which may lead to reduced CYP3A
activity (15,19,20). As studies in morbidly obese patients be-
fore and after bariatric surgery show a reduction in inflamma-
tion status in patients after bariatric surgery, it is hypothesized
that CYP3A activity in patients after bariatric surgery recovers
(21,22). However, it seems that the inflammation status does
not completely change back to non-obese (never been obese)
individuals, as 6 months post surgery values of leptin,
adiponectin and C-reactive protein (CRP) did not return to
values found for lean (never been obese) patients (21).
Midazolam is considered a model substrate drug for
CYP3A activity as it is primarily metabolized by CYP3A
(23). Therefore, in this study we aimed to evaluate the phar-
macokinetics of midazolam after oral and intravenous admin-
istration in a cohort of morbidly obese patients that was stud-
ied before and 1 year post bariatric surgery. The results are
used to evaluate consequences for dosing of midazolam in
patients after bariatric surgery.
MATERIALS AND METHODS
Study Design and Patients
This is a prospective observational and interventional study in
morbidly obese adult patients (NTC01519726, EudraCT
2011-003293-93). Before participation, all patients gave writ-
ten informed consent. The study was approved by the local
human research and ethics commit tee (VCMO,
NL35861.100.11) and was conducted according to the prin-
ciples of the Declaration of Helsinki (version 22-10-2008) and
in accordance with the Medical Research Involving Human
Subjects Act (WMO) of the Netherlands.
Morbidly obese patients undergoing a laparoscopic gastric
bypass or sleeve surgery between 18 and 65 years were eligible
for inclusion in the study. Patients were excluded if they used
CYP3A inducing or inhibiting medication (24), used products
containing grapefruit, wild grape, banpeiyu, pomegranate,
star fruit or black berry within 2 weeks before the study, were
pregnant, were breastfeeding, were younger than 18 or older
than 60 years or suffered from renal insufficiency (eGFR
MDRD4<60 mL/min).
Study Procedures
The study consisted of two occasions. The first occasion was
on the day of laparoscopic bariatric surgery (occasion 1), of
which the details and results have been described in a previous
report (25). One year after bariatric surgery, the 20 patients
who participated on occasion 1, were invited to participate in
the second part of the study (occasion 2). The period of 1 year
was chosen based on the Swedish Obese Subjects study show-
ing a mean weight loss optimum of 32% of body weight 0.5–
2 years after bariatric surgery (26).
For both occasions, patients fasted from midnight until the
study started in the morning (typically at 09:00 o’clock) and
were not allowed to eat or drink until 1 h post intravenous
midazolam dose. At first a 7.5 mg midazolam tablet was ad-
ministered orally and after 160±48 min an i.v. dose of 5 mg
was administered. For the first occasion, the i.v. dose coincid-
ed with the induction of anesthesia for the bariatric surgical
procedure while for the second occasion the i.v. dose was
administered at 150 min after oral dose. Blood samples were
collected at 5, 15, 30, 45, 55, 65, 75, 90, 120, 150 after oral
dose and at 5, 15, 30, 60, 90, 120, 150, 180, 240 and 300, 390
and 510min after intravenous dose at occasion 1, and at 5, 15,
30, 60, 90, 120, 150, 180, 240 and 300 min after intravenous
dose at occasion 2. After collection, blood samples were cen-
trifuged and plasma was stored at −80°C until analysis.
Samples were analyzed as described before (25). The
Richmond Agitation Sedation Scale (RASS) was used to score
the level of sedation in each participant after midazolam oral
dose until administration of the intravenous dose (27).
Population Pharmacokinetic Analysis and Internal
Validation
The population pharmacokinetic analyses was performed by
means of nonlinear mixed effects modelling using NONMEM
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(version 7.2) (28). Pirana (2.7.1) and R (2.15) were used to
visualize the data. Discrimination between different structural
and statistical models was made by comparison of the objec-
tive function value (OFV, i.e., −2 log likelihood [-2LL]). A p-
value below 0.05, representing a decrease of 3.84 in the OFV,
was considered statistically significant. In addition, goodness-
of-fit plots (observed versus individual-predicted concentra-
tions, observed versus population-predicted concentrations,
conditional weighted residuals versus time and versus
population-predicted concentrations plots) were used for di-
agnostic purposes. Furthermore, the confidence interval of the
parameter estimates, the correlation matrix and visual im-
provement of the individual plots were used to evaluate the
model. The internal validity of the population pharmacoki-
netic model was assessed by the bootstrap re-sampling method
using 500 replicates and normalized prediction distribution
errors (NPDE) (29). Parameters obtained with the bootstrap
replicates were compared with the estimates obtained from
the original dataset and NPDE plots were checked for normal
distribution characteristics and trends in the errors.
Midazolam concentration-time profiles were analysed sepa-
rately (occasion 1, occasion 2) and simultaneously (occasion 1 and
2). The separate pharmacokinetic analyses allowed for initial
exploration of the data and evaluation of covariate relationships
within each population. For all analyses, two- and three com-
partment pharmacokinetics models were tested. For the descrip-
tion of the oral absorption phase, different models were tested
including first order absorption, zero order absorption and a
transit compartment model in which transit compartment rates
(Ktr) were equalized to the absorption rate constant (Ka) (30).
Themean oral transit time (MTT), which represents the average
time for the drug from oral dose administration to appearance at
the sample site, can be calculated from Ktr using MTT = (N+
1)/Ktr in which N is the number of transit compartments. For
the statistical model, the individual parameter estimate
(Empirical Bayes Estimate or post hoc value) of the ith individual
was modelled according to (Eq. 1):
θi ¼ θmean  exp ηið Þ ð1Þ
where θmean is the population mean parameter value, and ηi is a
random variable for the ith individual with a mean of zero and
variance of ω2, assuming log-normal distribution in the popula-
tion. The residual variability, resulting from assay errors, model
misspecifications and other unexplained sources, was best de-
scribed with a proportional error model. The jth observed mid-
azolam concentration of the ith patient (Yij) in Eq. 2:
Y i j ¼ Cpred;i j  1þ εi j
  ð2Þ
where Cpred,ij is the population predicted midazolam concentra-
tion of the ith individual at the jth time, and εij is a
random variable with a mean of zero and variance of
σ2.
Covariate Analysis
Covariates were plotted independently against the individual
estimates of pharmacokinetic parameters to visualize potential
relations. The following covariates were tested: body weight,
BMI, lean body weight (31), age, sex and bariatric surgery.
The influence of the binary covariates bariatric surgery and
sex was explored by means of estimating two separate thetas
or by a factor (‘Z’) of increase/decrease according to Eq. 3:
Pi ¼ Pp  ZCOVARIATE ð3Þ
where Pi and Pp represent the individual and population
parameter estimate, Z represents the factor for increase or
decrease for the patients subgroup with a Z of 1 in case the
covariate equals 0 or a Z of Z in case the covariate equals 1. In
case the binary covariate bariatric surgery for a specific
parameter improved the model significantly, it was evaluated
whether this factor of increase or decrease could be related to
the difference in body weight, lean body weight (31) or BMI
between occasion 1 and 2 using the following equations:
If Occasion ¼ 1 : Pi ¼ Pp ð4Þ
If Occasion ¼ 2 : Pi ¼ Pp  factor⋅ COV BeforeSurgery−COV AfterSurgery
  ð5Þ
Furthermore, it was tested whether body weight, lean body
weight, age or BMI was a linear (Eq. 7) or nonlinear (Eq. 8)
covariate within occasion 1 or 2 using the following equations:
If Occasion ¼ 1 : Pi ¼ Pp ð6Þ
If Occasion ¼ 2 : Pi ¼ Pp  1þW  COV−COV medianð Þð ð7Þ
And/or:
If Occasion ¼ 2 : Pi ¼ Pp  COVCOV median
 X
ð8Þ
where Pi and Pp represent individual and population parameter
estimates, respectively; COV represents the covariate;
COVmedian represents the median covariate value; X represents
the exponential scaling factor; and W represents the correlation
factor between the population pharmacokinetic parameters and
the covariate. The occasion conditions were switched vice versa to
test covariate relationships within both groups.
Continuous covariates for both occasion 1 and 2 simulta-
neously were tested using linear and non-linear equations
(Eqs. 9 and 10).
Pi ¼ Pp  COVCOV median
 X
ð9Þ
Pi ¼ Pp  1þW  COV−COV medianð Þð ð10Þ
Potential covariates were separately entered into the model
and statistically tested by use of the OFV and, if applicable,
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the 95% CI of the additional parameter. In addition, if appli-
cable, it was evaluated whether the interindividual variability
in the parameter concerned reduced in value upon inclusion
of the covariate on the parameter. After forward inclusion
(p<0.05), a backward exclusion procedure was applied to jus-
tify the inclusion of a covariate (p<0.001). The choice of the
covariate model was further evaluated as discussed above (see
Population pharmacokinetic analysis and internal validation
section).
Model Simulations
The final population pharmacokinetic model was used to sim-
ulate the midazolam concentration time curves after a 7.5 mg
oral dose, a 5 mg intravenous dose and a 2.5 mg/h continuous
infusion. Using Monte Carlo simulations, 1000 individuals
were randomly generated based on body weight distribution
of our study (144±26 kg) and simulations based on theta and




Of the 20morbidly obese patients who participated in the first
part of the trial (occasion 1), 18 patients returned 52±3 weeks
after bariatric surgery (occasion 2) and lost a mean of 44.5±
10.2 kg of body weight. Two of the 20 patients were lost to
follow up to participate at occasion 2. Patients and study char-
acteristics are summarized in Table I. Figure 1 shows the
midazolam concentration time values measured at both study
occasions. At occasion 1, the occurrence of the peak concen-
trations after the i.v. dose were found to vary largely, which
resulted from differences in time of administration of the in-
travenous midazolam. For post-bariatric surgery patients, the
concentration time curves show a slightly earlier maximum
concentration (Cmax) after oral dose in comparison to morbid-
ly obese patients before bariatric surgery, while in a few indi-
viduals of the morbidly obese patient group peak concentra-
tions after the intravenous dose seemed higher.
Pharmacokinetic Analysis
For the population pharmacokinetic analysis including the
data of both occasions a three compartment model, in which
the second peripheral volume was a fraction of the first pe-
ripheral compartment best described the data. Midazolam
oral absorption was best described using five transit compart-
ments, while the addition of more transit compartments did
not further improve the fit of midazolam concentrations after
both oral and intravenous administration. Table II shows the
parameters estimates of the simple pharmacokinetic model
without covariates.
In the covariate analysis, the binary covariate ‘bariatric
surgery’ proved an important covariate for clearance (CL),










Age (years) 43.6±7.6 26–57 45.5±7.4 27–58
Body weight (kg) 144.4±21.7 112–186 98.3±18.0 62–138
LBW (kg) 71.5±11.9 53–95 59.5±10.0 39–73
BMI (kg/m2) 47.1±6.5 40–68 31.9±5.9 24–50
Weight loss (kg) – – 44.5±10.2 21–58
Number of midazolam samples per patient 22±3 13–24 21±1 19–22
Gastric bypass/ sleeve gastrectomy – – 16/2 –
Time post surgery (weeks) – – 51.8±2.5 49–57
BMI body mass index, LBW lean body weight

















Morbidly obese patients before bariatric
surgery (n=20)
Patients after bariatric surgery (n=18)
Fig. 1 Midazolam concentration versus time after oral dose profiles upon a
7.5 mg oral midazolam dose and a 5 mg intravenous dose separated by 160
±48 min in 20 morbidly obese patients before (black lines) and 1 year after
surgery (grey dotted lines). Two patients were unable to participate 1 year after
surgery.
3930 Brill et al.
oral absorption rate (Ka), inter compartmental clearance (Q)
and volumes of distribution (V). For clearance, the covariate
bariatric surgery gave the largest drop in OFV (−91 ΔOFV,
p<0.001), while a linear covariate relation with body weight
resulted in a drop in OFV (−80 ΔOFV). After bariatric sur-
gery, clearance was 1.68 times higher than in morbidly obese
patients before surgery, while the extent of this increase could
not be related to the loss in (lean) body weight (p>0.05,
Table II). Bariatric surgery as covariate on Ka also resulted
in an improved fit of the model (−167 ΔOFV, p<0.001). In
the final model, Ka was separately estimated for both occa-
sions and was found to have a larger value in patients after
bariatric surgery (0.117 versus 0.267 min−1, Table II). As a
consequence, the mean oral transit time (MTT), which is cal-
culated from the oral absorption rate, was 51.3 (15%) before
versus 22.6 (19%)minutes after bariatric surgery. Furthermore,
Table II Parameter Values of the Simple (Without Covariates) and Final (With Covariates) Population Pharmacokinetic Models and Results of the Bootstrap
Analysis
Parameter Simple model of simultaneous
analysis
Final model of simultaneous
analysis
Bootstrap of final simultaneous
model
Value (RSE) Value (RSE) Median (2.5–97.5 percentile)
Fixed effects
Ka = Ktr 0.199 (11%) – –
Ka = KtrMorbidly obese (min
−1) – 0.117 (15%) 0.114 (0.08–0.15)
Ka = KtrBariatric patients (min
−1) – 0.267 (19%) 0.263 (0.08–0.45)
F 0.560 (10%) 0.537 (9%) 0.543 (0.44–0.63)
CL (L/min) 0.381 (26%) – –
CLMorbidly obese (L/min) – 0.385 (11%) 0.366 (0.29–0.48)
fCLBariatric patients(L/min) – 1.68 (7%) (* CLmorbidly obese=0.647) 1.70 (1.18–2.18) (* CLmorbidly obese=0.634)
Q (L/min) 0.888 (21%) – –
QMorbidly obese (L/min) – 0.669 (24%) 0.764 (0.11–1.23)
fQBariatric patients (L/min) – 3.22 (32%) (* QMorbidly obese=2.15) 2.907 (−22.6–29.0) (*QMorbidly obese=3.71)
Q2 0.644 (21%) 0.551(23%) 0.548 (0.25–0.86)
Vcentral (L) 54.7 (17%) – –
Vcentral Morbidly obese = Vmedian BW *(1+X*(BW-median BW))
Vmedian BW – 37.3 (18%) 37.2 (17.8–56.8)
X – 0.0435 (92%) 0.052 (−0.42–0.51)
Vcentral Bariatric patients (L) – 37.3 (18%) 37.2 ()
V1st peripheral (L) 247 (30%) – –
VPeripheral Morbidly obese = Vmedian BW*(BW/median BW)
Y
Vmedian BW – 106 (17%) 113 (20.9–190.3)
Y – 3.93 (20%) 3.99 (1.9–5.9)
V1st peripheral Bariatric patients (L) – 106 (17%) 113 (1.9–5.9)
fV2nd peripheral 0.169 (25%) (*V1st peripheral=42 L) 0.359 (27%) (*V1st peripheral=38 L) 0.311 (0.13–0.58) (*V1st peripheral=40 L)
Interindividual variability (%)
Ktr = Ka 50 (17%) 42.4 (15%) 40.6 (27–54)
CL 41.5 (24%) 19.7 (38%) 17.7 (−14–32)
F 28.6 (23%) 33.4 (18%) 32.6 (16–45)
Vcentral 60.8 (20%) 53.7 (39%) 54.3 (−49–102)
V1st peripheral 0 FIX 0 FIX 0 FIX
Proportional residual error (%)
46.2 (6%) 42.1 (5%) 41.0 (12.2)
OFV 6218 5885 5997 (804)
BW body weight (median=127 kg for all data), CL Clearance (L/min), F Oral bioavailability, fCLBariatric patients(L/min) fraction of midazolam clearance of morbidly
obese patients to estimate bariatic patient clearance, fQBariatric patients fraction of intercompartmental clearance of morbidly obese patients to estimate
intercompartmental clearance of bariatric patients, fVperipheral fraction of first peripheral volume of distribution to estimate second peripheral volume, Ktr transit
compartment rate (min−1 ), Ka oral absorption rate (min−1 ), OFV Objective function value (-2LL), Q intercompartmental clearance (L/min), RSE(%) relative
standard error, V Volume of distribution (L), VPeripheral first peripheral volume of distribution
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bariatric surgery resulted in a 3.22 times increase in inter com-
partmental clearance, Q (0.669 to 2.15 L/min, −16 ΔOFV,
p<0.001). Finally, central and the peripheral volumes of distri-
bution were overall lower in patients after bariatric surgery
without a significant influence of (lean) bodyweight within this
group. In the morbidly obese patients group, central and pe-
ripheral volume increased with body weight (−6 ΔOFV,
p<0.02 and −68 ΔOFV, p<0.001, respectively, Table II). As
the second peripheral volume of distribution was modeled as a
fraction of the first peripheral volume of distribution, for mor-
bidly obese patients before surgery it varied with body weight in
a similar manner as the first peripheral volume of distribution
(Table II). Concerning oral bioavailability (F) and inter-
compartmental clearance to the second peripheral compart-
ment (Q2) none of the covariates were of significant influence
(p>0.05). Parameters estimates of the final pharmacokinetic
model are shown in Table II and goodness of fit plots are shown
in Fig. 2. A 500 replicate bootstrap showed validity of themodel
(94% successful, Table II) and NPDE plots are presented in
electronic supplementary material and showed a normal distri-
bution of errors without any trends for both occasions.
In Fig. 3 the population mean and 90% confidence interval
of 1000 Monte Carlo midazolam dose simulations for
morbidly obese patients before and after surgery are present-
ed. After a 5 mg intravenous dose, midazolam concentrations
in a bariatric surgery patient show a higher initial midazolam
concentration and a faster decline over time compared to a
morbidly obese patient before surgery (Fig. 3a). Upon a mid-
azolam 2.5 mg/h continuous infusion a bariatric patient is
exposed to a lower steady state concentration in comparison
to a morbidly obese patient (Fig. 3b), while steady state con-
centrations are reached approximately 2.5 times faster in bar-
iatric patients (~14 h) than in morbidly obese patient (~37 h).
Finally, oral midazolam in a bariatric patient will result in a
shorter time to maximum concentration (Tmax, 32 versus
65 min) and 1.5 times increase in midazolam Cmax in com-
parison to before surgery (Fig. 3c).
DISCUSSION
In this cohort study in which morbidly obese patients are
studied until 1 year after bariatric surgery, we aimed to deter-
mine how and to what extent midazolam pharmacokinetics
after oral and intravenous administration are affected by bar-
iatric surgery. One year post bariatric surgery, we found that
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Fig. 2 Observed versus individual
predicted midazolam
concentrations (a), observed versus
population predicted midazolam
concentrations (b), conditional
weighted residuals (CWRES) versus
time (c) and population predicted
midazolam concentrations (d) of
the final model for 20 morbidly
obese patients (black dots, occasion
1) of which 18 returned 1 year post
surgery for a second study visit (grey
dots, occasion 2). The dashed line
represents the line of identity (x=
y).
3932 Brill et al.
midazolam systemic clearance and mean oral transit time
were substantially increased while oral bioavailability
remained unchanged. Central and peripheral volumes of dis-
tribution were generally lower in patients after bariatric sur-
gery. The main finding of this study is the substantial increase
in midazolam systemic clearance in all 18 patients 1 year after
bariatric surgery compared to their values before surgery.
This increase in clearance after bariatric surgery could not
be contributed to the decrease in body weight as the body
weight model was inferior to the bariatric surgery model
(p<0.05). (Fig. 4). Hepatic CYP3A protein expression in liver
biopsies has been reported to be unaltered after bariatric sur-
gery indicating unchanged CYP3A mediated clearance (32).
However, Tandra et al. also found increased systemic clear-
ance of midazolam in 18 bariatric patients >1 year post
RYGB surgery in comparison with 18 controls (1.57±0.95
versus 0.92±0.72 L/min, p=0.03) (33). In their study, control
patients were matched for age, sex, race, and body mass in-
dex, while in our study we compared midazolam pharmaco-
kinetics within the same cohort using a follow up design.
Comparing our values to systemic clearance values in healthy
volunteers (Fig. 4a), it seems that systemic clearance values
post bariatric surgery are higher than those of healthy volun-
teers found in the literature (25,34–40). We anticipate that the
increase in systemic midazolam clearance may be explained
by a recovery of hepatic CYP3A activity due to decreased
inflammation status, as many studies have shown a reduction
in inflammatory adipokines in the plasma of patients after
bariatric surgery (22). Moreover, it has been shown in in vitro
and animal studies that a fatty liver, which is highly associated
with morbid obesity, represses CYP3A activity (41,42). While
CYP3A activity may have recovered 1 year after bariatric
surgery, Immonen et al. showed on the other hand that
6 months after bariatric surgery both the fat content and size
of the liver is reduced to almost the level of lean subjects,
which could imply a reduced clearance (21). The fact that
we identify in our study an increase in systemic midazolam
clearance post bariatric surgery implies that the increased
CYP3A activity per unit of liver compensates and surpasses
the reduction in liver size that is associated with bariatric sur-
gery in these patients. Another explanation could be a recov-
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CBA 5  mg intravenous dose 2.5 mg/h continuous infusion 7.5 mg oral dose
Fig. 3 Population mean (black line) and 90% interval (grey area) of midazolam concentrations versus time after a 5 mg intravenous dose (a), a 2.5 mg/h
continuous infusion (b) and a 7.5 mg oral dose (c) in morbidly obese patients before bariatric surgery (black solid line) and after bariatric surgery (black dotted line).
Fig. 4 Empirical bayes estimates (black dots) and population mean estimates (black lines) of midazolam clearance (a) and oral bioavailability (b) of the final
pharmacokinetic model in 20morbidly obese patients (black closed dots) and 18 bariatric patients (black open dots) versus body weight (kg). Parameter values found
for healthy volunteers studies from the literature were added for comparison (grey dots) (25,34–40).
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or steatosis (43), but as midazolam is an intermediate extrac-
tion ratio drug this seems unlikely (44).
Midazolam mean oral transit time was twice as fast in pa-
tients 1 year post bariatric surgery in comparison to before
surgery. Decreased Tmax in bariatric surgery patients has been
reported before for oral caffeine, tolbutamide, midazolam,
omeprazole and duloxetine administration (33,45). The faster
midazolam oral absorption may be explained by faster gastric
emptying of the stomach due to the reduced stomach size
(12,13,46,47). In contrast to more rapid oral absorption, for
oral bioavailability, we found no difference before and after
bariatric surgery. From a comparison to healthy volunteers
(Fig. 4b), it can be concluded that oral bioavailability values in
bariatric patients do not seem to return to values found for
healthy volunteers, but remain at the level of those found for
morbidly obese patients. The oral bioavailability value (F) may
be deduced to its individual contributors, which are the fraction
absorbed (fa), the fraction escaping gut wall metabolism (FG)
and the fraction escaping first pass hepatic metabolism (FH).
As midazolam is a highly soluble and permeable drug, fa
can be assumed to be equal to 1 in morbidly obese patients
before and after surgery (48). In addition, assuming no change
in hepatic blood flow and blood to plasma partition ratio
before and after surgery, FH will decrease approximately
1.68 times post bariatric surgery as a result of 1.68 times in-
creased systemic clearance. So, given the unchanged total bio-
availability, Ftotal, we identified in our study, this implies that
the midazolam fraction escaping gut wall (FG) increases 1.68
times 1 year after bariatric surgery. An increase in FG was also
predicted by Darwich et al., who showed that post RYGB
surgery the FG of CYP3A substrate simvastatin increased with
13% (49). Increased FG may be due to the bypass of the intes-
tines resulting from this type of surgery, in which normally
approximately 75% of the midazolam dose would have been
absorbed (48,50). Another explanation could be an increase in
splanchnic blood flow resulting in an increase in FG, however
this seems very unlikely in view of the decrease in bodyweight
associated with bariatric surgery and therefore an anticipated
decrease in splanchnic blood flow instead of increase.
For midazolam central and peripheral volume of distribu-
tion we observed overall lower values in post bariatric surgery
patients without variation due to body weight (p>0.05,
Table II). While we anticipate that this is due to the smaller
range in bodyweight in the bariatric patient group, as within
the morbidly obese patient group volume of distribution was
highly depended on body weight as was reported before (25).
To account for the influence of body weight on both the first
and second peripheral volume of distribution, the second pe-
ripheral volume was modeled as a fraction of the first volume
of distribution. The general reduction in volume of distribu-
tion after bariatric surgery may result from weight loss
resulting in substantial reductions in blood volume and adi-
pose tissue (51).
Although this study provides unique information on the
pharmacokinetics of midazolam after both oral and intrave-
nous dose administration in a new and emerging patient pop-
ulation, the study may have some limitations. First, 2 of the 18
patients underwent a sleeve gastrectomy procedure, which is
an insufficient number to draw any conclusion on the effect of
a sleeve gastrectomy on midazolam pharmacokinetics.
However, these 2 patients did show a major loss in body
weight to an extent that was similar to that of the 16 gastric
bypass patients, which was the reason why we included these
patients in the analysis. Moreover, when excluding these two
patients from the dataset, none of parameter estimates were
significantly different (data not shown). Second, at occasion 1,
patients underwent surgery and anesthesia, which was not the
case during occasion 2. This may potentially have influenced
the results on midazolam PK we report in this study. It is well
known that during a surgery cardiac output is lowered which
may have caused lower midazolam clearances for morbidly
obese patients. However, the duration of surgery and anesthe-
sia was quite limited (86.4±31 min) in comparison to the
study period of the first occasion (~660 min), minimizing the
influence of surgery. Moreover, bariatric surgery was per-
formed using minimally invasive techniques (laparoscopic
techniques) reducing hemodynamically induced changes.
Furthermore, surgery was performed 159±67 min after
oral midazolam dose administration, which excludes any
influence of surgery/anesthesia on midazolam the oral
absorption phase. For these reasons, we think that the
short duration of surgery/anesthesia during the first oc-
casion is not of significant influence on the conclusion
drawn based on these data.
The midazolam dose simulations provide insight in how
the altered pharmacokinetics in bariatric patients affect mid-
azolam concentration time profiles after oral or intravenous
administration. A 5 mg intravenous midazolam bolus dose
results in higher initial midazolam concentrations in a patient
post bariatric surgery than in a morbidly obese patient. This
indicates that, in comparison to morbidly obese patients, a
lower intravenous bolus dose may be anticipated in patients
post bariatric surgery, as after a intravenous bolus dose, mid-
azolam effect is primarily determined by the initial concentra-
tions. For an continuous intravenous infusion, a lower steady
state concentration is reached in a bariatric patient due to the
almost doubledmidazolam clearance value compared to mor-
bidly obese patients. So to reach a similar steady state concen-
tration in a bariatric patient a higher mg/h dose seems neces-
sary. In this respect, it is important to realise that a post-
bariatric surgery patient does not only need a higher dose than
before surgery but also may need a higher dose in mg/h than
a non-obese patient given the differences in clearance values
(Fig. 4). Furthermore, the steady state concentration is
reached 2.5 times faster in a bariatric surgery patient com-
pared to a morbidly obese patient. Finally, a midazolam oral
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tablet will result in increased Cmax and earlier Tmax in a bar-
iatric patient.
Finally, the influence of bariatric surgery on midazolam
systemic clearance found in this study may be extrapolated
to other drugs which are also primarily metabolised by
CYP3A, as midazolam is considered a CYP3A probe sub-
strate (23). While the extrapolation potential depends on
many factors, including extraction ratio and physico-
chemical properties of the drug, it may be speculated that
other major CYP3A substrates may show a similar effect of
bariatric surgery on systemic clearance.
CONCLUSION
In conclusion, in this cohort study in morbidly obese patients,
systemic clearance was 1.7 times higher 1 year after bariatric
surgery, which may potentially result from an increase in he-
patic CYP3A activity per unit of liver. Even though mean oral
transit time was found to be faster, oral bioavailability
remained unchanged, which considering the increased sys-
temic clearance implies an increase in the midazolam fraction
escaping intestinal first pass metabolism after an oral admin-
istration. In patients after a bariatric surgery, these alterations
will result in lower midazolam steady state concentrations and
in higher and earlier peak concentrations after oral adminis-
tration in comparison to morbidly obese patients before bar-
iatric surgery.
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